The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Open accessAbstract
BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS: Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [39]
In the citing paper
“First-line nivolumab + ipilimumab treatment also produced longer OS than chemotherapy in patients with advanced NSCLC10.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“First-line nivolumab + ipilimumab resulted in a longer duration of OS than chemotherapy in patients with metastatic NSCLC, irrespective of the PD-L1 expression10,28.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“most notably the combination of pembrolizumab and axitinib (an inhibitor of vascular growth factor inhibitor) in renal cell carcinoma.15”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [15]
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
In the citing paper
“Moreover, the data of CheckMate-214, CheckMate-227, and CheckMate-743 indicated the superior efficacy of ipilimumab plus nivolumab over the standard targeted therapy or chemotherapy [135–137].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,003
Chen, K., Wang, X., Yang, L., & Chen, Z. (2021) · Cancer Control · doi:10.1177/1073274821997430 · Cited by 67
Doki, Y., Ueno, M., Hsu, C., Oh, D., Park, K., Yamamoto, N., Ioka, T., Hara, H., Hayama, M., Nii, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4593 · Cited by 66
Self-citationAgostinetto, E., Eiger, D., Lambertini, M., Ceppi, M., Bruzzone, M., Ponde, N. F., Plummer, C., Awada, A. H., Santoro, A., Piccart, M. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.043 · Cited by 67
Parra, E. R., Ferrufino‐Schmidt, M. C., Tamegnon, A., Zhang, J., Solis, L. M., Jiang, M., Ibarguen, H. P., Haymaker, C., Lee, J. J., Bernatchez, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88156-0 · Cited by 66
Muto, S., Enta, A., Maruya, Y., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010190 · Cited by 68
Baxi, V., Lee, G., Duan, C., Pandya, D., Cohen, D. N., Edwards, R., Chang, H., Li, J., Elliott, H., Pokkalla, H., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01119-2 · Cited by 66
BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
Demerle, C., Gorvel, L., & Olive, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682007 · Cited by 68
An optimal portfolio of photothermal combined immunotherapy
Zeng, W., Li, Z., Chen, H., Zeng, X., & Mei, L. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.100898 · Cited by 66
Kato, K., Doki, Y., Ogata, T., Motoyama, S., Kawakami, H., Ueno, M., Kojima, T., Shirakawa, Y., Okada, M., Ishihara, R., et al. (2022) · Esophagus · doi:10.1007/s10388-022-00970-1 · Cited by 65
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 68
Hegewisch‐Becker, S., Mendez, G. A., Chao, J., Němeček, R., Feeney, K., Cutsem, E. V., Al‐Batran, S., Mansoor, W., Maisey, N. R., Pazo-Cid, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01636 · Cited by 68
Ye, J., Ji, X., Dennis, P. A., Abdullah, H. A., & Mukhopadhyay, P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1956 · Cited by 69
Sui, X., Han, X., Chen, P., Wu, Q., Feng, J., Duan, T., Chen, X., Pan, T. S., Yan, L., Jin, T., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.2139/ssrn.3667646 · Cited by 64
Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Franklin, M. R., Platero, S. J., Saini, K. S., Curigliano, G., & Anderson, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003231 · Cited by 69
Kato, K., Doki, Y., Chau, I., Xu, J., Wyrwicz, L. S., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C., Adenis, A., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7235 · Cited by 64
Lordick, F., Mauer, M., Stocker, G., Cella, C. A., Ben‐Aharon, I., Piessen, G., Wyrwicz, L., Al-Haidari, G., Fleitas, T., Boige, V., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.829 · Cited by 64
Domen, A., Quatannens, D., Zanivan, S. R., Deben, C., Audenaerde, J. R. M. V., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., et al. (2021) · Cancers · doi:10.3390/cancers13050987 · Cited by 64
Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 67
Self-citationTargeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
Deng, J., Zhou, M. L., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., Zhou, E., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818453 · Cited by 63
Neal, J. W., Pavlakis, N., Kim, S., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A. S., Christoph, D. C., Bearz, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02166 · Cited by 67
Self-citationWang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 65
Self-citationBotticelli, A., Cirillo, A., Scagnoli, S., Cerbelli, B., Strigari, L., Cortellini, A., Pizzuti, L., Vici, P., Galitiis, F. D., Pietro, F. R. D., et al. (2020) · Vaccines · doi:10.3390/vaccines8020203 · Cited by 63
Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., Sini, C., Grassi, M., Bello, M. G. D., Coco, S., et al. (2020) · Cancers · doi:10.3390/cancers12051125 · Cited by 61
Banna, G. L., Signorelli, D., Metro, G., Galetta, D., Toma, A. D., Cantale, O., Banini, M., Friedlaender, A., Pizzutilo, P., Garassino, M. C., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-583 · Cited by 60
Banna, G. L., Cortellini, A., Cortinovis, D. L., Tiseo, M., Aerts, J. G. J. V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100078 · Cited by 61
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 66
Bone metastases in non-small cell lung cancer: a narrative review
Knapp, B. J., Devarakonda, S. H. K., & Govindan, R. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1502 · Cited by 62
Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 63
Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61
Kovacs, S., & Győrffy, B. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03409-4 · Cited by 58
Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
Hu, Z. I., Link, V. M., Lima-Junior, D. S., Delaleu, J., Bouladoux, N. J., Han, S., Collins, N., & Belkaid, Y. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200348119 · Cited by 61
Kim, H., Park, S., Han, K.-Y., Lee, N., Kim, H. M., Jung, H. A., Sun, J., Ahn, J. S., Ahn, M., Lee, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005509 · Cited by 65
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
Tsukita, Y., Tozuka, T., Kushiro, K., Hosokawa, S., Sumi, T., Uematsu, M., Honjo, O., Yamaguchi, O., Asao, T., Sugisaka, J., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6277 · Cited by 72
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Ma, X., Zhang, Y., Wang, S., Wei, H., & Yu, J. (2021) · Journal of Cancer · doi:10.7150/jca.49174 · Cited by 62
Dong, Y., Wong, J. S. L., Sugimura, R., Lam, K. O., Li, B. K., Kwok, G. W., Leung, R. C.-Y., Chiu, J. W. Y., Cheung, T. T., & Yau, T. C. C. (2021) · Cancers · doi:10.3390/cancers13081949 · Cited by 59
Hosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61
Tian, Y., Zhai, X., Yan, W., Zhu, H., & Yu, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3590 · Cited by 58
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 57
Stares, M., Ding, T.-E., Stratton, C., Thomson, F., Baxter, M. A., Cagney, H. P., Cumming, K., Swan, A. M., Ross, F., Barrie, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100445 · Cited by 58
Zhou, K., Cao, J., Lin, H., Liang, L., Shen, Z., Wang, L., Peng, Z., & Mei, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962173 · Cited by 62
VISTA expression and patient selection for immune-based anticancer therapy
Martin, A. S., Molloy, M., Ugolkov, A. V., Roemeling, R. W. V., Noelle, R. J., Lewis, L. D., Johnson, M. L., Radvanyi, L. G., & Martell, R. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086102 · Cited by 59
Ding, H., Xin, W., Tong, Y., Sun, J., Xu, G., Ye, Z., & Rao, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238536 · Cited by 60
Enright, T. L., Witt, J. S., Burr, A. R., Yadav, P., Leal, T. A. B., & Baschnagel, A. M. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.014 · Cited by 60
From trends to transformation: where cardio-oncology is to make a difference
Herrmann, J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz781 · Cited by 59
The Landscape of Immunotherapy Resistance in NSCLC
Frisone, D., Friedlaender, A., Addeo, A., & Tsantoulis, P. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817548 · Cited by 60
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 58
Subudhi, S. K., Siddiqui, B. A., Aparicio, A. M., Yadav, S. S., Basu, S., Chen, H., Jindal, S., Tidwell, R. S. S., Varma, A., Logothetis, C. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002919 · Cited by 58
Kroemer, G., & Zitvogel, L. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201979 · Cited by 62
Zhan, L., Feng, H.-F., Liu, H., Guo, L., Chen, C., Yao, X.-L., & Sun, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649863 · Cited by 62
Liu, C., Wang, M., Xu, C., Li, B., Chen, J., Chen, J., & Wang, Z. (2021) · Journal of Immunology Research · doi:10.1155/2021/8970173 · Cited by 60
Cousin, F., Louis, T., Dheur, S., Aboubakar, F., Ghaye, B., Occhipinti, M., Vos, W., Bottari, F., Paulus, A., Sibille, A., et al. (2023) · Cancers · doi:10.3390/cancers15071968 · Cited by 51
Wagner, G., Stollenwerk, H. K., Klerings, I., Pecherstorfer, M., Gartlehner, G., & Singer, J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774314 · Cited by 60
Wiesweg, M., Mairinger, F. D., Reis, H., Goetz, M., Kollmeier, J., Misch, D., Stephan-Falkenau, S., Mairinger, T., Walter, R. F. H., Hager, T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.015 · Cited by 56
Vellanki, P. J., Mulkey, F. A., Jaigirdar, A. A., Rodríguez, L., Wang, Y., Xu, Y., Zhao, H., Liu, J., Howe, G. A., Wang, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4338 · Cited by 60
Deschênes‐Simard, X., Richard, C., Galland, L., Blais, F., Desîlets, A., Malo, J., Cvetkovic, L., Belkaïd, W., Elkrief, A., Gagné, A., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.06.018 · Cited by 57
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
Xue, J., Zhu, Y., Bai, S., He, C., Du, G., Zhang, Y., Zhong, Y. H., Chen, W., Wang, H., & Sun, X. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.020 · Cited by 56
Chu, X., Niu, L., Xiao, G., Peng, H., Deng, F., Liu, Z., Wu, H., Yang, L., Tan, Z., Li, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875488 · Cited by 58
Bacterial outer membrane vesicle-based cancer nanovaccines
Gao, X., Feng, Q., Wang, J., & Zhao, X. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0452 · Cited by 56
Hong, L., Aminu, M., Li, S., Lu, X., Petranović, M., Saad, M. B., Chen, P., Qin, K., Varghese, S., Rinsurongkawong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36328-z · Cited by 56
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Frontline immunotherapy for NSCLC — the tale of the tail
Chiang, A. C., & Herbst, R. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0317-y · Cited by 57
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 57
Su, W., Wang, L., Zhao, H., Hu, S., Zhou, Y., Guo, C., Wu, B., Li, L., Yang, Z., Beer, D. G., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.025 · Cited by 54
de Mello, R. A., Neves, N. M., Tadokoro, H., Amaral, G. A., Castelo‐Branco, P., & Zia, V. A. D. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113543 · Cited by 59
Bravaccini, S., Bronte, G., & Ulivi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126536 · Cited by 60
Kehl, K. L., Zahrieh, D. M., Yang, P., Hillman, S. L., Tan, A. D., Sands, J. M., Oxnard, G. R., Gillaspie, E. A., Wigle, D. A., Malik, S. M., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0039 · Cited by 55
Self-citationJiang, M., Hu, Y., Lin, G., & Chen, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906251 · Cited by 59
Godoy, L. A., Chen, J., Ma, W., Lally, J., Toomey, K. A., Rajappa, P., Sheridan, R., Mahajan, S., Stollenwerk, N. S., Phan, C. T., et al. (2023) · Biomarker Research · doi:10.1186/s40364-022-00444-7 · Cited by 62
Federico, A. D., Alden, S. L., Smithy, J. W., Ricciuti, B., Alessi, J. V., Wang, X., Pecci, F., Lamberti, G., Gandhi, M. M., Vaz, V. R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.014 · Cited by 57
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 72
Kim, C. G., Kim, G., Kim, K. H., Park, S., Shin, S., Yeo, D., Shim, H. S., Yoon, H. I., Park, S. Y., Ha, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002780 · Cited by 57
The advanced development of molecular targeted therapy for hepatocellular carcinoma
Yan, T., Yu, L., Zhang, N., Peng, C., Su, G., Jing, Y., Zhang, L., Wu, T., Cheng, J., Guo, Q., et al. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0661 · Cited by 55
Borghaei, H., O'Byrne, K. J., Paz-Ares, L. G., Ciuleanu, T.-E., Yu, X., Płużański, A., Nagrial, A. M., Havel, L., Kowalyszyn, R. D., Audigier-Valette, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102065 · Cited by 57
Self-citationNano-formulations in disease therapy: designs, advances, challenges, and future directions
Shi, Y., Li, X., Li, Z., Sun, J., Gao, T., Wei, G., & Guo, Q. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03442-7 · Cited by 58
Quinn, C., Garrison, L., Pownell, A., Atkins, M., de Pouvourville, G., Harrington, K., Ascierto, P., McEwan, P., Wagner, S., Borrill, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000648 · Cited by 49
Makunts, T., Saunders, I. M., Cohen, I. V., Li, M., Moumedjian, T., Issa, M. A., Burkhart, K., Lee, P., Patel, S. P., & Abagyan, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-96467-5 · Cited by 56
Management of immune-related cutaneous adverse events with dupilumab
Kuo, A. M.-S., Gu, S., Stoll, J. R., Moy, A. P., Dusza, S. W., Gordon, A., Haliasos, E. C., Janjigian, Y. Y., Kraehenbuehl, L., Quigley, E. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007324 · Cited by 55
Iivanainen, S., Ekström, J., Virtanen, H., Kataja, V. V., & Koivunen, J. P. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01564-0 · Cited by 55
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
Rodriguez, J. E., Naigeon, M., Goldschmidt, V., Dugage, M. R., Seknazi, L., Danlos, F., Champiat, S., Marabelle, A., Michot, J., Massard, C., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2098718 · Cited by 55
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 52
Provencio, M., Granados, A. L. O., Coves-Sarto, J., Calvo, V., Fabregat, R. M., Dómine, M., Guirado, M., Carcereny, E., Fernández, N., Álvarez, R., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5959 · Cited by 52
Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 53
Tsai, Y.-T., Schlom, J., & Donahue, R. N. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02969-1 · Cited by 56
Shiraishi, Y., Nomura, S., Sugawara, S., Horinouchi, H., Yoneshima, Y., Hayashi, H., Azuma, K., Hara, S., Niho, S., Morita, R., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00185-1 · Cited by 54
Eze, C., Schmidt-Hegemann, N.-S., Sawicki, L. M., Kirchner, J., Roengvoraphoj, O., Käsmann, L., Mittlmeier, L. M., Kunz, W. G., Tufman, A., Dinkel, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05211-8 · Cited by 54
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 52
Self-citationCurrent Status in Rechallenge of Immunotherapy
Hu, H. H., Wang, K., Jia, R., Zeng, Z., Zhu, M., Deng, Y., Xiong, Z., Tang, J., Xie, H., Wang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82776 · Cited by 52
Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 61
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
Li, K., Liu, C., Sui, X., Li, C., Zhang, T., Zhao, T., Zhang, D., Wu, H., Liu, Y., Wang, S., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.05.011 · Cited by 59
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Self-citationCombination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 66
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 52
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non–small cell lung cancer
Li, K., Zheng, X., Tang, H., Zang, Y., Zeng, C., Liu, X., Shen, Y., Pang, Y., Wang, S., Xie, F., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210151 · Cited by 52
Rybkin, I. I., & Gadgeel, S. M. (2022) · Medical radiology · doi:10.1007/174_2022_313 · Cited by 51
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
Koustas, E., Sarantis, P., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Biomolecules · doi:10.3390/biom10050666 · Cited by 55
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
Banna, G. L., Cantale, O., Bersanelli, M., Re, M. D., Friedlaender, A., Cortellini, A., & Addeo, A. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.490 · Cited by 50
Zhao, Y., Hao, C., Li, M., Qu, Y., Guo, Y., Deng, X., Si, H., & Yao, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112768 · Cited by 49
Metadata
- Authors
- Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O’Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Universidad Complutense de Madrid (ES)
- From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology–Germans Trias i Pujol Hospital, Badalona (E.C.C.) — all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2020-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2976744492
- Cited by
- 2,823
- References
- 26
- Citations by year
- 2026: 183 · 2025: 316 · 2024: 399 · 2023: 448 · 2022: 516 · 2021: 570 · 2020: 368 · 2019: 18
- FWCI
- 154.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- ipilimumab, non-small cell lung cancer, PD-L1 expression, immune checkpoint inhibitors, combination immunotherapy, overall survival, chemotherapy, PD-1, CTLA-4, long-term benefits, PD-L1-negative tumors, stage IV lung cancer, recurrent lung cancer, immune-related adverse events, immune-related pneumonitis
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
